Rephrase and rearrange the whole content into a news article. I want you to respond only in language English. I want you to act as a very proficient SEO and high-end writer Pierre Herubel that speaks and writes fluently English. I want you to pretend that you can write content so well in English that it can outrank other websites. Make sure there is zero plagiarism.:
Jonathan Raa | Nurphoto | Getty Images
Novo Nordisk shares climbed 5% on Thursday morning, according to LSEG data, hitting a fresh record highs after the Danish pharmaceutical giant reported positive early trial data for a new experimental weight loss drug.
The company told an investor meeting that the Phase I trial of its highly-anticipated obesity drug amycretin showed a 13.1% weight loss in participants after 12 weeks, according to Reuters. This reading eclipses the 6% loss recorded after a 12-week trial for the company’s wildly popular obesity drug Wegovy.
A Phase II trial will begin in the second half of this year, with results expected in early 2026, the company said.
Shares of Novo Nordisk, Europe’s largest company by market cap, have gained more than 27% since the turn of the year as the pharmaceuticals giant continues to reap the benefits of rampant demand for its flagship Wegovy and Ozempic anti-obesity drugs.
Earlier this week, Novo reported late-stage trial results showing that Ozempic cut the risk of kidney disease progression and death from kidney or cardiovascular complications by 24% in diabetic patients with chronic kidney disease.
The results added to mounting evidence of the broader health benefits associated with Ozempic and similar drugs, beyond weight loss and Type 2 diabetes treatment.
Shares of American rival Eli Lilly were down 1.3% in after hours trading on the back of the news.
I have over 10 years of experience in the cryptocurrency industry and I have been on the list of the top authors on LinkedIn for the past 5 years. I have a wealth of knowledge to share with my readers, and my goal is to help them navigate the ever-changing world of cryptocurrencies.
